BELLUS Health Inc  

(Public, TSE:BLU)   Watch this stock  
Find more results for BLU
0.235
0.000 (0.00%)
Jul 22 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.23 - 0.25
52 week 0.20 - 2.99
Open 0.23
Vol / Avg. 131,676.00/627,824.00
Mkt cap 13.49M
P/E     -
Div/yield     -
EPS -0.01
Shares 61.06M
Beta 2.26
Inst. own     -
Aug 10, 2016
Q2 2016 BELLUS Health Inc Earnings Release (Estimated) Add to calendar
Jun 20, 2016
BELLUS Health announces top-line Phase 3 results of KIACTAT for the treatment of AA amyloidosis Corporate Presentation
May 12, 2016
BELLUS Health Inc Annual Shareholders Meeting
May 12, 2016
Q1 2016 BELLUS Health Inc Earnings Release
May 2, 2016
BELLUS Health Inc at Bloom Burton & Co. Healthcare Investor Conference
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -128.43% 10.06%
Operating margin -115.57% -2.63%
EBITD margin - -2.63%
Return on average assets -21.03% 2.55%
Return on average equity -33.17% 2.32%
Employees 9 -
CDP Score - -

Address

275 Armand-Frappier Blvd
LAVAL, QC H7V 4A7
Canada
+1-450-6804500 (Phone)
+1-450-6804501 (Fax)

Website links

Description

BELLUS Health Inc. is a drug development company focused on rare diseases. The business activities of the Company are development of the Company's core technology platform, amyloid inhibitors, which focus on chemical compounds that could have the potential to inhibit the formation, deposition and toxicity of amyloid fibrils, which are the underlying causes of certain diseases. The Company operates in the business segment of development of drugs for health solutions. It is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. Its pipeline of rare disease projects includes KIACTA in Phase III for Amyloid A (AA) amyloidosis; KIACTA for sarcoidosis; clinical stage Shigamab for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS), and a research-stage project for amyloid light-chain (AL) amyloidosis. It is partnered with global private equity firm Auven Therapeutics for the development of KIACTA.